
Photo: Created with AI
Get the latest FDA updates on medication recalls, manufacturing violations, and quality concerns that could affect your prescriptions

Photo: Created with AI
Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we cover a recall for amiodarone and FDA medication health fraud warnings about Ismerely Mire-X and Yuan Bone arthritis supplements. We’re also including a warning letter sent to Rohto-Mentholatum regarding its eye drop products.
Consumers may wish to check the linked enforcement report for the list of affected product lot numbers and expiration dates. For prescription drugs that don’t include a lot number on the packaging, consumers may check with their pharmacist to see whether a medication is affected by the recall.
The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or “not yet classified.”
While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.
Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 days.
FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of FDA laws, including violations of “current good manufacturing practices for finished pharmaceuticals” or unapproved new drugs. The violations lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.
Drug Purpose: Treats life-threatening, uncontrolled, irregular heartbeat problems (ventricular arrhythmias) when other treatments don’t work or are not tolerated. Also sometimes used off-label to control heart rhythm in patients with atrial fibrillation (AFib). Because of the risk of life-threatening toxicity, this medication is to be used under hospital or specialist supervision.
Company: Unichem Pharmaceuticals USA Inc., East Brunswick, New Jersey
Manufacturing Location: Ghaziabad, India, by Unichem Laboratories Ltd.
Scope: 23,850 60-count bottles of 200 mg tablets
Recall Reason: Presence of a foreign substance
Recall Initiation Date: October 30, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Drug Purpose: Over-the-counter topical wash for treating acne
Company: Advanced Cosmetic Research Laboratories, Inc.
Manufacturing Location: Not specified; Distributed by Shield Skin LLC, Miami, FL
Scope: 25,023 8.5 fl oz/250 mL bottles distributed in New York only
Recall Reason: CGMP (Current Good Manufacturing Practice) deviations; this could affect product quality.
Recall Initiation Date: October 23, 2026
Recall Level: Class II
Link: FDA Enforcement Report
Product Purpose: Promoted and sold for joint pain relief
Scope: Sold on various websites, including eBay.com, and possibly in some retail stores.
Warning: The FDA advises consumers not to purchase or use Ismerely Mire-X because laboratory analysis confirmed the product contains diclofenac (an anti-inflammatory pain reliever) and dexamethasone (a steroid medication) not listed on the product label.
Warning Date: November 12, 2026
Link: Press Release and Health Fraud Product Database (Pain and Arthritis Products)
Check the Press Release for product photo and more information on this warning.
Product Purpose: Promoted and sold for relief of joint pain, aches, pains, and osteoarthritis.
Scope: Sold on various websites, including “www.vietnamus.store,” and possibly in some retail stores.
Warning: The FDA is advising consumers not to purchase or use Yuan Bone because laboratory analysis confirmed the product contains acetaminophen (a pain reliever), chlorpheniramine (an antihistamine), and diclofenac (an anti-inflammatory pain reliever) not listed on the product label.
Warning Date: November 12, 2026
Link: Press Release and Health Fraud Product Database (Pain and Arthritis Products)
Check the Press Release for product photo and more information on this warning.
Type: Manufacturer of over-the-counter drugs
FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)
Warning Letter Date: October 14, 2026.
Facility Location: Ho Chi Minh, Vietnam
Dates of Inspection: April 6 to April 14, 2026; Rohto sent its first response to the FDA Form 483 inspection report on May 1, 2026.
Types of Products Made: Over-the-counter (OTC) topical ophthalmic drug products, including Rohto brand eye drops
Warning: The FDA warned Rohto-Mentholatum about product quality and data integrity problems. It also warned that Rohto had “misbranded drug violations.”
Inspectors also found significant problems with the company’s environmental monitoring and cleaning records. Employees documented cleaning procedures that had never been performed, while numerous samples showing microbial growth were inaccurately reported as having no detectable microbial contamination. The company reported only one exception, following a water leak.
The FDA also cited poor aseptic practices, inadequate protective clothing, and equipment that obstructed airflow intended to prevent contamination. Two batches were shipped to the United States despite unusually high rates of rejected bottles during visual inspections, and without an adequate investigation of the particles found or their source.
Consumer complaints dating back to 2019 described leaking bottles, bottles with floating particles, burning, stinging, worsening redness, and blurry vision. Yet the company recorded “no need” or “NA” for corrective action.
Separately, in August 2026, the FDA reviewed the company’s product labels, website, and Instagram account and identified seven ROHTO Cooling Eye Drops products as unapproved new drugs and misbranded: COOL RELIEF, ALL-IN-ONE, MAX STRENGTH, DIGI EYE, OPTIC GLOW, DRY AID, and DUAL LIGHT RELIEF.
The agency cited claims that the drops strengthen the eye’s lipid film, improve tear-film stability, provide up to eight hours of cooling and soothing relief, and alleviate digital eye strain. The FDA determined that these claims established intended drug uses for which the products lacked the required approval.
Essential Extras:
The warning letter indicated that the following actions have been taken as a result of the FDA findings:
Link: FDA Warning Letter and Recall Enforcement Report
Read the warning letter for a complete description of violations.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowIndependent, science-based health journalism. Free every Friday. No pharma funding.
We seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.
We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.
As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:
1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:
This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.
2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.
3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.
4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.
If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org
We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.
For website editors
Copy the article body, including its formatting and links, then paste it into your publishing system. Add the byline and required credit described in these guidelines.
<!-- wp:paragraph -->
<p>Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we cover a recall for amiodarone and FDA medication health fraud warnings about Ismerely Mire-X and Yuan Bone arthritis supplements. We’re also including a warning letter sent to Rohto-Mentholatum regarding its eye drop products.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Consumers may wish to check the linked enforcement report for the list of affected product lot numbers and expiration dates. For prescription drugs that don’t include a lot number on the packaging, consumers may check with their pharmacist to see whether a medication is affected by the recall. </p>
<!-- /wp:paragraph -->
<!-- wp:group {"layout":{"type":"constrained"}} -->
<div class="wp-block-group"><!-- wp:heading -->
<h2 class="wp-block-heading">How To Read This Report</h2>
<!-- /wp:heading -->
<!-- wp:accordion -->
<div role="group" class="wp-block-accordion"><!-- wp:accordion-item -->
<div class="wp-block-accordion-item"><!-- wp:accordion-heading -->
<h3 class="wp-block-accordion-heading has-icon has-icon-right"><button type="button" class="wp-block-accordion-heading__toggle"><span class="wp-block-accordion-heading__toggle-title">Recalls (Enforcement Reports Database)</span><span class="wp-block-accordion-heading__toggle-icon" aria-hidden="true">+</span></button></h3>
<!-- /wp:accordion-heading -->
<!-- wp:accordion-panel -->
<div role="region" class="wp-block-accordion-panel"><!-- wp:paragraph -->
<p>The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or "not yet classified."</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.</p>
<!-- /wp:paragraph -->
<!-- wp:list -->
<ul class="wp-block-list"><!-- wp:list-item -->
<li>Class I recalls are the most serious. In these situations, there is "reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death."</li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Class II recalls are for drugs that may cause temporary or medically reversible adverse health consequences or where use of the product is unlikely to result in serious adverse health consequences.</li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Class III recalls are the least serious. Use of the product is not likely to cause adverse health consequences.</li>
<!-- /wp:list-item --></ul>
<!-- /wp:list --></div>
<!-- /wp:accordion-panel --></div>
<!-- /wp:accordion-item --></div>
<!-- /wp:accordion -->
<!-- wp:accordion -->
<div role="group" class="wp-block-accordion"><!-- wp:accordion-item -->
<div class="wp-block-accordion-item"><!-- wp:accordion-heading -->
<h3 class="wp-block-accordion-heading has-icon has-icon-right"><button type="button" class="wp-block-accordion-heading__toggle"><span class="wp-block-accordion-heading__toggle-title">Warning Letters (Warning Letters Database)</span><span class="wp-block-accordion-heading__toggle-icon" aria-hidden="true">+</span></button></h3>
<!-- /wp:accordion-heading -->
<!-- wp:accordion-panel -->
<div role="region" class="wp-block-accordion-panel"><!-- wp:paragraph -->
<p>Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 days.</p>
<!-- /wp:paragraph --></div>
<!-- /wp:accordion-panel --></div>
<!-- /wp:accordion-item --></div>
<!-- /wp:accordion -->
<!-- wp:accordion -->
<div role="group" class="wp-block-accordion"><!-- wp:accordion-item -->
<div class="wp-block-accordion-item"><!-- wp:accordion-heading -->
<h3 class="wp-block-accordion-heading has-icon has-icon-right"><button type="button" class="wp-block-accordion-heading__toggle"><span class="wp-block-accordion-heading__toggle-title">Drug Imports Alerts Database</span><span class="wp-block-accordion-heading__toggle-icon" aria-hidden="true">+</span></button></h3>
<!-- /wp:accordion-heading -->
<!-- wp:accordion-panel -->
<div role="region" class="wp-block-accordion-panel"><!-- wp:paragraph -->
<p>FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of <a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211">FDA laws</a>, including violations of “current good manufacturing practices for finished pharmaceuticals” or <a href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-99">unapproved new drugs</a>. The violations lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.</p>
<!-- /wp:paragraph --></div>
<!-- /wp:accordion-panel --></div>
<!-- /wp:accordion-item --></div>
<!-- /wp:accordion --></div>
<!-- /wp:group -->
<!-- wp:heading -->
<h2 class="wp-block-heading">Drug Recalls</h2>
<!-- /wp:heading -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Amiodarone Hydrochloride Tablets (generic for Cordarone, which has been discontinued)</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose:</strong> Treats life-threatening, uncontrolled, irregular heartbeat problems (ventricular <a href="https://www.texasheart.org/heart-health/heart-information-center/topics/categories-of-arrhythmias/">arrhythmias</a>) when other treatments don’t work or are not tolerated. Also sometimes used off-label to control heart rhythm in patients with atrial fibrillation (AFib). Because of the risk of life-threatening toxicity, this medication is to be used under hospital or specialist supervision.<br><strong>Company</strong>: Unichem Pharmaceuticals USA Inc., East Brunswick, New Jersey<br><strong>Manufacturing Location</strong>: Ghaziabad, India, by Unichem Laboratories Ltd.<br><strong>Scope</strong>: 23,850 60-count bottles of 200 mg tablets<br><strong>Recall Reason</strong>: Presence of a foreign substance<br><strong>Recall Initiation Date</strong>: October 30, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100290">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Shield Labs Body Acne Wash (benzoyl peroxide 10%)</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Drug Purpose</strong>: Over-the-counter topical wash for treating acne<br><strong>Company</strong>: Advanced Cosmetic Research Laboratories, Inc.<br><strong>Manufacturing Location</strong>: Not specified; Distributed by Shield Skin LLC, Miami, FL<br><strong>Scope</strong>: 25,023 8.5 fl oz/250 mL bottles distributed in New York only<br><strong>Recall Reason</strong>: CGMP (Current Good Manufacturing Practice) deviations; this could affect product quality.<br><strong>Recall Initiation Date</strong>: October 23, 2026<br><strong>Recall Level</strong>: Class II<br><strong>Link</strong>: <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=100219">FDA Enforcement Report</a></p>
<!-- /wp:paragraph -->
<!-- wp:heading -->
<h2 class="wp-block-heading">Supplements Containing Medication</h2>
<!-- /wp:heading -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Ismerely Mire-X Tablets</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Product Purpose</strong>: Promoted and sold for joint pain relief<br><strong>Scope</strong>: Sold on various websites, including eBay.com, and possibly in some retail stores. <br><strong>Warning</strong>: The FDA advises consumers not to purchase or use Ismerely Mire-X because laboratory analysis confirmed the product contains diclofenac (an anti-inflammatory pain reliever) and dexamethasone (a steroid medication) not listed on the product label.</p>
<!-- /wp:paragraph -->
<!-- wp:list -->
<ul class="wp-block-list"><!-- wp:list-item -->
<li>Diclofenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is often prescribed to treat arthritis-related pain and inflammation. <a href="https://medlineplus.gov/druginfo/meds/a689002.html">Oral formulations</a> of diclofenac (which are only available by prescription) have a boxed warning about the risk of serious heart problems, such as heart attack and stroke, and gastrointestinal effects, such as bleeding, ulcers, or life-threatening tears in the stomach or intestinal lining. Diclofenac can interact with other medications, especially other NSAID-containing products, and may significantly increase the risk of these serious side effects.<br></li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Dexamethasone is a steroid medication commonly used to reduce inflammation. However, it can weaken the immune system, making it harder for the body to fight infections. It can also cause high blood sugar, muscle damage, and mental health problems.<br></li>
<!-- /wp:list-item --></ul>
<!-- /wp:list -->
<!-- wp:paragraph -->
<p><strong>Warning Date</strong>: November 12, 2026<br><strong>Link</strong>: <a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/ismerely-mire-x-may-be-harmful-due-hidden-ingredients">Press Release</a> and <a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients">Health Fraud Product Database</a> (Pain and Arthritis Products)<br>Check the Press Release for product photo and more information on this warning.</p>
<!-- /wp:paragraph -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Yuan Bone Capsules</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Product Purpose</strong>: Promoted and sold for relief of joint pain, aches, pains, and osteoarthritis.<br><strong>Scope</strong>: Sold on various websites, including “www.vietnamus.store,” and possibly in some retail stores. <br><strong>Warning</strong>: The FDA is advising consumers not to purchase or use Yuan Bone because laboratory analysis confirmed the product contains acetaminophen (a pain reliever), chlorpheniramine (an antihistamine), and diclofenac (an anti-inflammatory pain reliever) not listed on the product label.</p>
<!-- /wp:paragraph -->
<!-- wp:list -->
<ul class="wp-block-list"><!-- wp:list-item -->
<li>Acetaminophen is used to temporarily relieve pain and reduce fever. Taking too much acetaminophen can cause liver damage, ranging from mild liver problems to complete liver failure and death.<br></li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Chlorpheniramine is an antihistamine and may cause drowsiness and make it harder to think clearly or stay alert.<br></li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Diclofenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is often prescribed to treat arthritis-related pain and inflammation. <a href="https://medlineplus.gov/druginfo/meds/a689002.html">Oral formulations</a> of diclofenac (which are only available by prescription) have a boxed warning about the risk of serious heart problems, such as heart attack and stroke, and gastrointestinal effects, such as bleeding, ulcers, or life-threatening tears in the stomach or intestinal lining. Diclofenac can interact with other medications, especially other NSAID-containing products, and may significantly increase the risk of these serious side effects.</li>
<!-- /wp:list-item --></ul>
<!-- /wp:list -->
<!-- wp:paragraph -->
<p><strong>Warning Date</strong>: November 12, 2026<br><strong>Link</strong>: <a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/yuan-bone-may-be-harmful-due-hidden-ingredients">Press Release</a> and <a href="https://www.fda.gov/drugs/medication-health-fraud-notifications/pain-and-arthritis-products-containing-hidden-ingredients">Health Fraud Product Database</a> (Pain and Arthritis Products)<br>Check the Press Release for product photo and more information on this warning.</p>
<!-- /wp:paragraph -->
<!-- wp:heading -->
<h2 class="wp-block-heading">FDA Warning Letters</h2>
<!-- /wp:heading -->
<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Rohto-Mentholatum (Vietnam) Co., Ltd.</h3>
<!-- /wp:heading -->
<!-- wp:paragraph -->
<p><strong>Type</strong>: Manufacturer of over-the-counter drugs<br><strong>FDA Department Issuing Warning</strong>: Center for Drug Evaluation and Research (CDER)<br><strong>Warning Letter Date</strong>: October 14, 2026.<br><strong>Facility Location</strong>: Ho Chi Minh, Vietnam<br><strong>Dates of Inspection</strong>: April 6 to April 14, 2026; Rohto sent its first response to the FDA Form 483 inspection report on May 1, 2026.<br><strong>Types of Products Made</strong>: Over-the-counter (OTC) topical ophthalmic drug products, including Rohto brand eye drops<br><strong>Warning</strong>: The FDA warned Rohto-Mentholatum about product quality and data integrity problems. It also warned that Rohto had “misbranded drug violations.” </p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Inspectors also found significant problems with the company's environmental monitoring and cleaning records. Employees documented cleaning procedures that had never been performed, while numerous samples showing microbial growth were inaccurately reported as having no detectable microbial contamination. The company reported only one exception, following a water leak.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>The FDA also cited poor aseptic practices, inadequate protective clothing, and equipment that obstructed airflow intended to prevent contamination. Two batches were shipped to the United States despite unusually high rates of rejected bottles during visual inspections, and without an adequate investigation of the particles found or their source.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Consumer complaints dating back to 2019 described leaking bottles, bottles with floating particles, burning, stinging, worsening redness, and blurry vision. Yet the company recorded “no need” or “NA” for corrective action.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>Separately, in August 2026, the FDA reviewed the company’s product labels, website, and Instagram account and identified seven ROHTO Cooling Eye Drops products as unapproved new drugs and misbranded: COOL RELIEF, ALL-IN-ONE, MAX STRENGTH, DIGI EYE, OPTIC GLOW, DRY AID, and DUAL LIGHT RELIEF.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p>The agency cited claims that the drops strengthen the eye’s lipid film, improve tear-film stability, provide up to eight hours of cooling and soothing relief, and alleviate digital eye strain. The FDA determined that these claims established intended drug uses for which the products lacked the required approval.</p>
<!-- /wp:paragraph -->
<!-- wp:paragraph -->
<p><strong>Essential Extras:</strong><br>The warning letter indicated that the following actions have been taken as a result of the FDA findings:</p>
<!-- /wp:paragraph -->
<!-- wp:list -->
<ul class="wp-block-list"><!-- wp:list-item -->
<li>Drug Production Suspended: The FDA acknowledged Rohto’s commitment to suspend production of all drugs made at this facility for the U.S. market. In response to the warning letter, Rohto must clarify whether it intends to resume manufacturing drugs for the U.S. market in the future. If it resumes manufacturing, it must resolve all deficiencies and systemic flaws to ensure ongoing <a href="https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations">Current Good Manufacturing Practice (CGMP)</a> compliance.</li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Recall: On July 14, 2026, Rohto initiated a <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99440">voluntary recall</a> of all lots of Rohto Cool Relief, Rohto All-In-One, Rohto Max Strength, Rohto Digi-Eye, Rohto Optic Glow, and Rohto Dry Aid, due to lack of sterility assurance.</li>
<!-- /wp:list-item -->
<!-- wp:list-item -->
<li>Import Alert: FDA placed all drugs and drug products from Mentholatum (Vietnam) Co., Ltd. on <a href="https://www.accessdata.fda.gov/CMS_IA/importalert_189.html">Import Alert 66-40</a> on August 13, 2026. The <a href="https://www.fda.gov/industry/actions-enforcement/import-alerts">import alert</a> allows the U.S. Customs and Border Protection (CBP) to detain drug products at the U.S. border without physically examining them. The importer can only overcome this import detention by demonstrating to the FDA that the product does not have the violation(s) listed on the import alert.</li>
<!-- /wp:list-item --></ul>
<!-- /wp:list -->
<!-- wp:paragraph -->
<p><strong>Link</strong>: <a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026">FDA Warning Letter</a> and <a href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99440">Recall Enforcement Report<br></a>Read the warning letter for a complete description of violations.</p>
<!-- /wp:paragraph -->We think it’s invaluable — and hope you agree. Our work is made possible by donations from readers like you.
We think it’s invaluable — and hope you agree. Our journalism is made possible by donations from readers like you.
As a nonprofit, we don’t take a dime from pharmaceutical or supplement companies. That means we can report on the benefits, risks, and alternatives to prescription and over-the-counter drugs free from corporate pressure or influence.